CYP1A2 and NAT2 phenotyping and 3-aminobiphenyl and 4-aminobiphenyl hemoglobin adduct levels in smokers and non-smokers

Toxicology and Applied Pharmacology

Volumn 213, Issue 3, 2006, Pages 198-206

  Sarkar, Mohamadi ^a,b   Stabbert, Regina ^c   Kinser, Robin D ^a   Oey, Jan ^a   Rustemeier, Klaus ^c   von Holt, Klaus ^c   Schepers, Georg ^c   Walk, Roger A ^a   Roethig, Hans J ^a  

^a Philip Morris USA   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c Philip Morris Research Laboratories GmbH   (Germany)

Author keywords

3 Aminobiphenyl; 4 Aminobiphenyl; Aromatic amines; Biomarkers; Bladder cancer; Cigarette smoke; Cytochrome P4501A2; Exposure study; Hemoglobin adducts; N acetyltransferase; Phenotype; Polymorphism; Risk; Tobacco smoke carcinogens

Indexed keywords

1 METHYXANTHINE; 1,7 DIMETHYLURIC ACID; 1,7 METHYXANTHINE; 3 BIPHENYLAMINE; 4 BIPHENYLAMINE; 5 ACETAMIDO 6 FORMYLAMINO 3 METHYLURACIL; AMINOBIPHENYL DERIVATIVE; ARYLAMINE ACETYLTRANSFERASE; BIOLOGICAL MARKER; CAFFEINE; CIGARETTE SMOKE; CYTOCHROME P450 1A2; HEMOGLOBIN; UNCLASSIFIED DRUG; XANTHINE DERIVATIVE;

ADULT; ARTICLE; BLOOD SAMPLING; CIGARETTE SMOKING; CONTROLLED STUDY; DOSE RESPONSE; EXPOSURE; FEMALE; GAS CHROMATOGRAPHY; HUMAN; HUMAN CELL; MALE; MASS SPECTROMETRY; NORMAL HUMAN; PHENOTYPE; SAMPLE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AMINOBIPHENYL COMPOUNDS; ARYLAMINE N-ACETYLTRANSFERASE; BIOLOGICAL MARKERS; CARCINOGENS; CYTOCHROME P-450 CYP1A2; FEMALE; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; PROTEIN BINDING; SMOKING;

EID: 33744519928     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2005.11.003     Document Type: Article

References (44)

1. Bartsch H., Caporaso N., Coda M., Kadlubar F., Malaveille C., Skipper P., Talaska G., Tannenbaum S.R., and Vineis P. Carcinogen hemoglobin adducts, urinary mutagenicity, and metabolic phenotype in active and passive cigarette smokers. J. Natl. Cancer Inst. 82 (1990) 1826-1831
2. Branner B., Krutzer W., Zwickenpflug W., Scherer G., Heller W.D., and Richter E. Hemoglobin adducts from aromatic amines and tobacco-specific nitrosamines in pregnant smoking and non-smoking women. Biomarkers 3 (1998) 35-47
3. Bryant M.S., Skipper P.L., Tannenbaum S.R., and Maclure M. Hemoglobin adducts of 4-aminobiphenyl in smokers and nonsmokers. Cancer Res. 47 (1987) 602-608
4. Bryant M.S., Vineis P., Skipper P.L., and Tannenbaum S.R. Haemoglobin adducts of aromatic amines in people exposed to cigarette smoke. IARC Sci. (1988) 133-136
5. Bryant M.S., Vineis P., Skipper P.L., and Tannenbaum S.R. Hemoglobin adducts of aromatic amines: associations with smoking status and type of tobacco. Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 9788-9791
6. Butler M.A., Iwasaki M., Guengerich F.P., and Kadlubar F.F. Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc. Natl. Acad. Sci. U.S.A. 86 (1989) 7696-7700
7. Butler M.A., Lang N.P., Young J.F., Caporaso N.E., Vineis P., Hayes R.B., Teitel C.H., Massengill J.P., Lawsen M.F., and Kadlubar F.F. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 2 (1992) 116-127
8. Chiang T.A., Pei-Fen W., Ying L.S., Wang L.F., and Ko Y.C. Mutagenicity and aromatic amine content of fumes from heated cooking oils produced in Taiwan. Food Chem. Toxicol. 37 (1999) 125-134
9. Dallinga J.W., Pachen D.M., Wijnhoven S.W., Breedijk A., van 't Veer L., Wigbout G., van Zandwijk N., Maas L.M., van Agen E., Kleinjans J.C., and Van Schooten F.J. The use of 4-aminobiphenyl hemoglobin adducts and aromatic DNA adducts in lymphocytes of smokers as biomarkers of exposure. Cancer Epidemiol., Biomarkers Prev. 7 (1998) 571-577
10. Fontana R.J., Lown K.S., Paine M.F., Fortlage L., Santella R.M., Felton J.S., Knize M.G., Greenberg A., and Watkins P.B. Effects of a chargrilled meat diet on expression of CYP3A, CYP1A, and P-glycoprotein levels in healthy volunteers. Gastroenterology 117 (1999) 89-98
11. Fuhr U., Rost K.L., Engelhardt R., Sachs M., Liermann D., Belloc C., Beaune P., Janezic S., Grant D., Meyer U.A., and Staib A.H. Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations. Pharmacogenetics 6 (1996) 159-176
12. Grant D.M., Morike K., Eichelbaum M., and Meyer U.A. Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver. J. Clin. Invest. 85 (1990) 968-972
13. Hein D.W. Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutat.Res. 506-507 (2002) 65-77
14. Hein D.W., Doll M.A., Rustan T.D., Gray K., Feng Y., Ferguson R.J., and Grant D.M. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis 14 (1993) 1633-1638
15. Hein D.W., Doll M.A., Fretland A.J., Leff M.A., Webb S.J., Xiao G.H., Devanaboyina U.S., Nangju N.A., and Feng Y. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol., Biomarkers Prev. 9 (2000) 29-42
16. Hiromon A., Nyland L., Kociba P., Hungafvel P.K., and Vainio H. Modulation of urinary mutagenicity by genetically determined metabolism in smokers. Carcinogenesis 15 (1994) 813-815
17. International Agency for Research on Cancer, 1987. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Lyon, France, IARC.
18. IARC. Monographs on the evaluation of carcinogenic risks to humans. Tobacco Smoke and Involuntary Smoking vol. 83 (2004), World Health Organization-International Agency for Research on Cancer, Lyon, France
19. Jones C.R., and Sabbioni G. Identification of DNA adducts using HPLC/MS/MS following in vitro and in vivo experiments with arylamines and nitroarenes. Chem. Res. Toxicol. 16 (2003) 1251-1263
20. Kadlubar F.F., Miller J.A., and Miller E.C. Hepatic microsomal N-glucuronidation and nucleic acid binding of N-hydroxy arylamines in relation to urinary bladder carcinogenesis. Cancer Res. 37 (1977) 805-814
21. Kadlubar F.F., Dooley K.L., Teitel C.H., Roberts D.W., Benson R.W., Butler M.A., Bailey J.R., Young J.F., Skipper P.W., and Tannenbaum S.R. Frequency of urination and its effects on metabolism, pharmacokinetics, blood hemoglobin adduct formation, and liver and urinary bladder DNA adduct levels in beagle dogs given the carcinogen 4-aminobiphenyl. Cancer Res. 51 (1991) 4371-4377
22. Kimura S., Kawabe M., Ward J.M., Morishima H., Kadlubar F., Hammons G.J., Salguero P.F., and Gonzalez F.J. CYP1A2 is not the primary enzyme responsible for 4-aminoibiphenyl hepatocarcinogenesis in mice. Carcinogenesis 20 (1999) 1825-1830
23. Kutzer C., Branner B., Zwickenpflug W., and Richter E. Simultaneous solid-phase extraction and gas chromatographic-mass spectrometric determination of hemoglobin adducts from tobacco-specific nitrosamines and aromatic amines. J. Chromatogr. Sci. 35 (1997) 1-6
24. Landi M.T., Zocchetti C., Bernucci I., Kadlubar F.F., Tannenbaum S., Skipper P., Bartsch H., Malaveille C., Shields P., Caporaso N.E., and Vineis P. Cytochrome P4501A2: enzyme induction and genetic control in determining 4-aminobiphenyl-hemoglobin adduct levels. Cancer Epidemiol., Biomarkers Prev. 5 (1996) 693-698
25. Lilienblum W., Platt K.L., Schirmer G., Oesch F., and Bock K.W. Regioselectivity of rat liver microsomal UDP-glucuronosyltransferase activities toward phenols of benzo(a)pyrene and dibenz(a,h)anthracene. Mol. Pharmacol. 32 (1987) 173-177
26. Maclure M., Katz R.B., Bryant M.S., Skipper P.L., and Tannenbaum S.R. Elevated blood levels of carcinogens in passive smokers. Am. J. Public Health 79 (1989) 1381-1384
27. Mooney L.A., Santella R.M., Covey L., Jeffrey A.M., Bigbee W., Randall M.C., Cooper T.B., Ottman R., Tsai W.Y., and Wazneh L. Decline of DNA damage and other biomarkers in peripheral blood following smoking cessation. Cancer Epidemiol., Biomarkers Prev. 4 (1995) 627-634
28. Myers S.R., Spinnato J.A., Pinorini-Godly M.T., Cook C., Boles B., and Rodgers G.C. Characterization of 4-aminobiphenyl-hemoglobin adducts in maternal and fetal blood-samples. J. Toxicol. Environ. Health 47 (1996) 553-566
29. Pavanello S., Simioli P., Lupi S., Gregorio P., and Clonfero E. Exposure levels and cytochrome P450 1A2 activity, but not N-acetyltransferase, glutathione S-transferase (GST) M1 and T1, influence urinary mutagen excretion in smokers. Cancer Epidemiol., Biomarkers Prev. 11 (2002) 998-1003
30. Platzek T., Lang C., Grohmann G., Gi U.S., and Baltes W. Formation of a carcinogenic aromatic amine from an azo dye by human skin bacteria in vitro. Hum. Exp. Toxicol. 18 (1999) 552-559
31. Poupko J.M., Hearn W.L., and Radomski J.L. N-Glucuronidation of N-hydroxy aromatic amines: a mechanism for their transport and bladder-specific carcinogenicity. Toxicol. Appl. Pharmacol. 50 (1979) 479-484
32. Probst-Hensch N.M., Bell D.A., Watson M.A., Skipper P.L., Tannenbaum S.R., Chan K.K., Ross R.K., and Yu M.C. N-acetyltransferase 2 phenotype but not NAT1*10 genotype affects aminobiphenyl-hemoglobin adduct levels. Cancer Epidemiol., Biomarkers Prev. 9 (2000) 619-623
33. Richfield-Fratz N., Bailey Jr. J.E., and Bailey C.J. Determination of unsulfonated aromatic amines in FD and C Yellow No. 6 by the diazotization and coupling procedure followed by reversed-phase high-performance liquid chromatography. J. Chromatogr. 331 (1985) 109-123
34. Richfield-Fratz N., Baczynskyj W.M., Miller G.C., and Bailey Jr. J.E. Isolation, characterization and determination of trace organic impurities in FD and C red no. 40. J. Chromatogr. 467 (1989) 167-176
35. Sabbioni G. Hemoglobin binding of monocyclic aromatic amines: molecular dosimetry and quantitative structure activity relationships for the N-oxidation. Chem.-Biol. Interact. 81 (1992) 91-117
36. Sabbioni G. Hemoglobin binding of aromatic amines: molecular dosimetry and quantitative structure-activity relationships for N-oxidation. Environ. Health Perspect. 99 (1993) 213-216
37. Sabbioni G., and Neumann H.G. Biomonitoring of arylamines: hemoglobin adducts of urea and carbamate pesticides. Carcinogenesis 11 (1990) 111-115
38. Sarkar M., Nseyo U., and Zhong B.Z. Mutagenic outcome of the urinary carcinogen 4-aminobiphenyl is increased in acidic pH. Environ. Toxicol. 11 (2002) 23-26
39. Sugimura T. A view of a cancer researcher on environmental mutagens. In: Sugimura T. (Ed). Environmental Mutagens and Carcinogens (1982), Alan R. Liss, New York 3-20
40. Vineis P., Caporaso N., Tannenbaum S.R., Skipper P.L., Glogowski J., Bartsch H., Coda M., Talaska G., and Kadlubar F. Acetylation phenotype, carcinogen-hemoglobin adducts, and cigarette smoking. Cancer Res. 50 (1990) 3002-3004
41. Vineis P., Talaska G., Malaveille C., Bartsch H., Martone T., Sithisarankul P., and Strickland P. DNA adducts in urothelial cells: relationship with biomarkers of exposure to arylamines and polycyclic aromatic hydrocarbons from tobacco smoke. Int. J. Cancer 65 (1996) 314-316
42. Weisburger J.H., and Weisburger E.K. Chemicals as causes of cancer. Chem. Eng. News 7 (1966) 125-142
43. Yu M.C., Skipper P.L., Taghizadeh K., Tannenbaum S.R., Chan K.K., Henderson B.E., and Ross R.K. Acetylator phenotype, aminobiphenyl-hemoglobin adduct levels, and bladder cancer risk in white, black, and Asian men in Los Angeles, California. J. Natl. Cancer Inst. 86 (1994) 712-716
44. Zedler, B., Kinser, R.D., Oey, J., Nelson, B., Roethig, H.-J., Walk, R.A., in press. Biomarkers of exposure and potential harm in adult smokers of 3 to 7 mg tar yield (FTC) cigarettes and in adult non-smokers. Biomarkers.